Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisanne P Zijlker

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
European Journal of Cancer (Oxford, England : 1990)|November 24, 2022
The end of wide local excision (WLE) margins for melanoma ?Lisanne P Zijlker, Alexander M M Eggermont, Alexander C J van Akkooi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 9, 2022
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and TimingAlexander C J van Akkooi, Lisanne P Zijlker, Michel W J M Wouters
Cancer|October 3, 2023
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete responseLisanne P Zijlker, Sonja Levy, Wendy Wolters, et al.
Melanoma Research|November 28, 2023
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanomaEmma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, et al.
BMC Cancer|August 4, 2022
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trialMaartje W Rohaan, Emma H A Stahlie, Viola Franke, et al.
Journal of Surgical Oncology|December 27, 2022
Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinomaLisanne P Zijlker, Max Bakker, Bernies van der Hiel, et al.
Annals of Surgical Oncology|December 18, 2025
Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous MelanomaLisanne P Zijlker, Zahra Verwer, Bart A van der Wiel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2023
Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgeryLisanne P Zijlker, Stijn J C van der Burg, Christian U Blank, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 17, 2024
The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)Carl-Jacob Holmberg, Lisanne P Zijlker, Dimitrios Katsarelias, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
European Journal of Cancer (Oxford, England : 1990)|November 24, 2022
The end of wide local excision (WLE) margins for melanoma ?Lisanne P Zijlker, Alexander M M Eggermont, Alexander C J van Akkooi
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 9, 2022
Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and TimingAlexander C J van Akkooi, Lisanne P Zijlker, Michel W J M Wouters
Cancer|October 3, 2023
Avelumab treatment for patients with metastatic Merkel cell carcinoma can be safely stopped after 1 year and a PET/CT-confirmed complete responseLisanne P Zijlker, Sonja Levy, Wendy Wolters, et al.
Melanoma Research|November 28, 2023
Real-world relapse-free survival data on adjuvant anti-PD-1 therapy for patients with newly diagnosed and recurrent stage III melanomaEmma H A Stahlie, Lisanne P Zijlker, Michel W J M Wouters, et al.
BMC Cancer|August 4, 2022
Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trialMaartje W Rohaan, Emma H A Stahlie, Viola Franke, et al.
Journal of Surgical Oncology|December 27, 2022
Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinomaLisanne P Zijlker, Max Bakker, Bernies van der Hiel, et al.
Annals of Surgical Oncology|December 18, 2025
Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous MelanomaLisanne P Zijlker, Zahra Verwer, Bart A van der Wiel, et al.
European Journal of Cancer (Oxford, England : 1990)|March 29, 2023
Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgeryLisanne P Zijlker, Stijn J C van der Burg, Christian U Blank, et al.
The Oncologist|November 19, 2024
Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanomaJeffrey Weber, Waqas Haque, Svetomir N Markovic, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|March 17, 2024
The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial)Carl-Jacob Holmberg, Lisanne P Zijlker, Dimitrios Katsarelias, et al.
Pageof 2